RET and non-small cell lung carcinoma: In contrast to activation by fusion mutations seen in NSCLC and PTC cancers, multiple endocrine neoplasia type 2 (MEN2) syndromes display RET point mutations that cluster in the cysteine-rich domain in exons 10, 11, and the tyrosine kinase domains in exons 13 and 16 [81,82].